Kornimate/medical-research-clean huggingface dataset:
natural killer index from hematopoietic stem cell graft

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloblastic Leukemia; Chronic Myeloid Leukemia

Summary: numerous studies about the potential role of nk alloreactive during a n hematopoietic stem cells graft are based on genotypical analyses of the kir receptors and on genotypic incompatibilities between kir and hla for couple donor/recipient. there is still a lot of issues non resolved: are kir really expressed and how occur their expression during time when hematopoietic reconstitution? is it depending on hla of the recipient?if kir are expressed, what are the mechanisms of alloreactivity of nk cells? are nk able to lyse tumoral cells? could alloreactive nk cells constitute a therapeutic tool able to induce tolerance and elimination of leukemia during hematopoietic stem cells grafts?


Eligibility criteria:
inclusion criteria: * age superior to 1 year * patient that will be treated by an hsc graft * initial pathology of recipient: acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic myeloid leukemia exclusion criteria: * patient already included in a study with an exclusion period * hiv + or hcv + serology during pre-graft analysis * patient already treated by an allograft of hsc

Keywords: recipient of a hsc graft in acute myeloblastic leukemia therapy recipient of a hsc graft in others pathologies treated in hematology of nantes university hospital or angers university hospital donors are healthy subjects
descartes: de-escalation of radiotherapy in patients with pathologic complete response to neoadjuvant systemic therapy

Conditions: Breast Cancer

Summary: this study evaluates whether radiotherapy can safely be omitted in breast cancer patients with t1-2n0 tumors who achieve a pathologic complete response after neoadjuvant systemic therapy and breast-conserving surgery

the proportion of women diagnosed with breast cancer who are treated with neoadjuvant systemic therapy is increasing. depending on the subtype, 10-75% of these patients will have a pathologic complete response. currently breast conserving surgery with pathologic complete response is followed by radiotherapy. in this patient group risk of local recurrence is low, but radiotherapy may cause considerable morbidity. the aim of this study is to investigate whether omitting radiotherapy is safe for patients with a node-negative breast tumor \<5cm treated with neoadjuvant systemic therapy and breast conserving surgery who achieve a pathologic complete response

Eligibility criteria:
inclusion criteria: * women, aged ≥ 18 years * invasive hr positive/her2 negative, her2+ (er/pr +/-) or tn breast cancer * concurrent dcis in pre-nst biopsy is allowed if there is no suspicion of extensive component i.e. absence of non-mass enhancement on pre-nst mri, contrast-enhanced mammography or breast-specific gamma imaging and/or absence of calcifications on pre-nst mammography * primary tumour (t) clinical stage ct1-2 * unifocal disease; confirmed by pre-nst mri, contrast-enhanced mammography or breast-specific gamma imaging * clinical nodal stage 0; absence of lymph node metastases should be confirmed by ultrasound or fdg-pet/ct * neoadjuvant systemic treatment (nst) * marker placed in breast tumour prior to nst * breast conserving surgery performed, i.e. no mastectomy * sentinel node biopsy performed before or after nst * pathologic complete response in breast and lymph nodes, i.e. no residual tumour cells or dcis detected * written informed consent exclusion criteria: * primary tumour (t) clinical stage ct3-4 * pre- or post-nst diagnosis of nodal disease including isolated tumour cells * patients without axillary ultrasound or fdg-pet/ct pre-nst * history of breast cancer or dcis * synchronous contralateral breast cancer or dcis * synchronous m1 disease * carrier of gene mutation associated with increased risk of breast cancer, i.e. brca1, brca2, chek2, tp53 or palb-2

Keywords: neoadjuvant chemotherapy breast cancer complete response radiotherapy
group preconception care for fertility patients

Conditions: Infertility

Summary: group preconception care for fertility patients aims to translate the well-established group prenatal care model to preconception care to improve pregnancy and neonatal outcomes. in partnership with pomelo care (a virtual maternity care program), the investigators are conducting this study using couples at penn fertility care.


Eligibility criteria:
inclusion criteria: 1. female new patient seen at penn fertility care for infertility or procreative management 2. currently planning to conceive 3. intending to carry pregnancy (i.e. will not need a gestational carrier), since our project aims to implement lifestyle changes prior to conception 4. willing to be randomized to group preconception care versus usual care exclusion criteria: 1. prior infertility treatment at other practice in this initial project, we aim to focus on patients with a new diagnosis of infertility to allow time for completion of the virtual program during the diagnostic phase and early treatment phase 2. known need for gestational carrier, as above 3. planning preimplantation genetic testing for monogenic disorders or egg/embryo banking 4. non-english speaking 5. unable to complete electronic questionnaires due to lack of access to technology
study of the efficacy of ggro: a novel cognitive training app

Conditions: Obsessive Thoughts

Summary: the aim of the present study was to evaluate the efficacy of ggro reducing ocd related maladaptive beliefs and ocd symptoms. specifically, a randomized controlled trial with crossover design was carried out in non-clinical population to assess pre-post changes in levels of ocd-related maladaptive beliefs and ocd symptoms, including relationship ocd (rocd) symptoms, self-esteem, and depressive symptoms following 15 days of using ggro.

the implementation of information and communication technologies in the treatment or prevention of ocd symptoms has been significantly lower compared to with its application in other anxiety disorders. recently, an exploratory study evaluated a brief, game-like, training exercise for challenging ocd-beliefs delivered via a mobile application platform named ggro. however, more studies are needed to test the efficacy.

Eligibility criteria:
inclusion criteria: * being a spanish at native level, and having a mobile device capable of installing the application ggro exclusion criteria: * none

Keywords: obsessive compulsive disorder cognitive therapy maladaptive beliefs mobile app
ultrasound-guided continuous low serratus anterior plane block in hepatocellular carcinoma surgery

Conditions: Liver Neoplasms; Postoperative Analgesia; Serratus Anterior Plane Block

Summary: to investigate the clinical application of ultrasound-guided continuous low serratus anterior plane block in open surgery for hepatocellular carcinoma.

methods: patients with hepatocellular carcinoma who attended our hospital from january 2021 to april 2023 were divided into cs group and n group according to the random number table method; cs group underwent ultrasound-guided continuous low anterior serratus plane block and n group underwent ultrasound-guided single anterior serratus plane block combined with rectus abdominis sheath block; the operation time, anesthesia time, incision length, sensory block time and sensory block maintenance time were counted and recorded. pain score (nrs) was used to detect analgesia; alanine aminotransferase (alt), liver function aspartate aminotransferase (ast), and prothrombin time (the time of thrombin, nrs) were measured by fluorescent quantitative pcr. （the time of thrombin (aptt), total bilirubin (tbil) levels and adverse reactions.

Eligibility criteria:
inclusion criteria: 1. age 18-60 years; 2. asai-ii; 3. bmi: 18-29 kg/m2 exclusion criteria: 1. combined cardiac, cerebral, hepatic, and renal failure; 2. comorbid psychiatric and neuromuscular disorders; 3. a history of allergy to anesthetic drugs; 4. participation in other recent clinical or drug trials.

Keywords: serratus anterior plane block postoperative analgesia liver cancer
cardiac rehabilitation in coronary artery diseases

Conditions: Have a Diagnosis of Coronary Artery Disease

Summary: cardiac rehabilitation is approaches that focus on accelerating the recovery process of patients after a cardiac event, improving their physical, psychological and social conditions, and controlling risk factors. cardiac rehabilitation is known to be an effective and cost-effective approach in the secondary prevention of cardiovascular diseases, most of which are caused by preventable risks. ischemic heart diseases, one of the cardiovascular diseases, are responsible for 16% of total deaths in the world and have increased significantly since 2000, causing 8.9 million deaths in 2019. when coronary artery diseases cannot be prevented, the basic approach should be to ensure the individual's compliance with treatment and healthy lifestyle behaviors, and to increase the quality of life and life span. for this reason, the aim of the study is to examine the effects of technology-based education structured according to the health promotion model in cardiac rehabilitation on healthy lifestyle behaviors, health fatalism and risk knowledge level. question 1. does technology-based education structured according to the health promotion model affect the healthy lifestyle behaviors score? question 2. does technology-based education structured according to the health promotion model affect the health fatalism score? question 3. does technology-based education structured according to the health promotion model affect the cardiovascular disease risk factors knowledge level score?


Eligibility criteria:
inclusion criteria: * having a diagnosis of coronary artery disease (acute coronary syndrome, coronary revascularization, atherosclerotic heart disease, etc.), * being stable in health (the patient's health status does not change suddenly and is under control), * if an interventional procedure has been performed, at least three months have passed after discharge, * being between the ages of 18-65, * being literate, * using smart phone and internet, * living in the city center exclusion criteria: * having a disability (vision, hearing, neurological, cognitive, etc.) that may interfere with education, * cardiac rehabilitation is contraindicated * to have participated in a cardiac rehabilitation program given by another institution before or during the study,

Keywords: nursing cardiac rehabilitation health promotion model healthy lifestyle behaviors health fatalism
comparison of azathioprine to methotrexate in combination therapy with adalimumab in crohn's disease: an open-label randomized controlled trial

Conditions: Crohn Disease; Azathioprine; Methotrexate

Summary: combination therapy, the association of an anti-tumor necrosis factor (tnf) to an immunosuppressant, is recognized as the most effective treatment during crohn's disease (cd). several mechanisms have been proposed to explain the superiority of combination therapy over monotherapy, the additive effect of two effective drugs or the prevention of anti-tnf immunogenicity. as the best combination therapy is unknown, both azathioprine (aza) and methotrexate (mtx) are used. some retrospective studies suggest a higher effectiveness of aza. mtx may have an advantage in terms of safety. the investigators hypothesize that aza is more effective than mtx as combination therapy with adalimumab to improve short-term endoscopic, clinical and pharmacological outcomes in cd patients.


Eligibility criteria:
inclusion criteria: * male or female patients with age \> 18 years * crohn's disease for at least 6 weeks, * clinically active with cdai \> 150 * active inflammation by endoscopy (cdeis \> 4) at baseline * not responder to conventional therapy or are intolerant to or have medical contraindications for such therapies and initiating treatment with adalimumab * patient followed in a center belonging to the getaid network * fertile men and women of childbearing potential included in the protocol should use adequate methods of contraception according to study drug smpcs. * written consent exclusion criteria: * short bowel syndrome, ostomy, symptomatic stricture, abscess, recent history of abdominal surgery (\<3 months) * non-passable colonic stricture * previous intolerance to thiopurines or mtx * previous exposition to adalimumab * contra-indication to immunosuppressants or anti-tnf * others serious simultaneous illness that could interfere with study participation * planning pregnancy, pregnancy or lactation or absence of contraception * known substance abusers * use of any investigational drug within 30 days * adults protected by law

Keywords: crohn disease combinations of therapy anti-tumor necrosis factor azathioprine methotrexate
combination of lymphatico-venular anastomosis and liposuction in treating lymphedema

Conditions: Description of an Effective Surgical Strategy to Treat Cancer Related Lymphedema, a High Incidence Pathology

Summary: * cooperation of an international team with many years of experience in surgical management of lymphedema * description of an effective surgical strategy to treat cancer-related lymphedema, a high incidence pathology * the combination of lva and liposuction guarantees long lasting results

cancer-related lymphedema represents one of the major complications of cancer treatment, especially for breast and gynecologic cancers. moreover, it has high impact on cancer survivors and healthcare systems. lymphedema management still remains challenging. the better understanding of lymphedema physiopathology as well as the development of sophisticated surgical and diagnostic techniques have led to effective strategies to address lymphedema patients but, despite the considerable interest in international literature, no consensus exist. the authors present a retrospective analysis of 24 consecutive patients affected by cancer-related lymphedema treated by the combination of lva and liposuction in the same surgical session. patients data regarding limb volume, lymphangitis rate and quality of life index were assessed before surgery and 1 year after surgery. one year after surgery an average volume reduction of 37,9% was registered. lymphangitis rate significantly decreased after surgery to 0.95 per year. quality of life score improved. conclusions the combination of lva and liposuction represents an effective strategy in treating patients with cancer-related lymphedema, ensuring a significant decrease in volume and reduction of lymphangitis rate as well as stable results in time. in addition, it appears to be minimally invasive and well tolerated by patients, since it can be performed under local anesthesia with low risk of complications.

Eligibility criteria:
inclusion criteria: previous lymphadenectomy exclusion criteria: free from cancer related pathology

Keywords: lymphedema lva liposuction treatment
safety and efficacy of unrelated umbilical cord blood microtransplantation in patients with higher-risk mds

Conditions: Myelodysplastic Syndromes

Summary: this study aimed to evaluate the safety and efficacy of unrelated umbilical cord blood microtransplantation in the treatment of above-mentioned mds patients by observing the factors related to the efficacy and adverse reactions.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with mds with who criteria through bone marrow morphology, histochemistry, immunophenotyping, pathological testing, etc. patients can be newly diagnosed, recurrent or unresponsive, with international prognostic scoring system (ipss-r) score\> 3.5 2. patients aged 14-80, gender and race are not limited; 3. karnofsky score ≥ 60%, eastern cooperative oncology group (ecog) performance status ≤ 2; 4. expected survival time ≥ 3 months; 5. the examination results meet the following requirements: alt and ast ≤ 3 × upper limit of normal value (uln); total bilirubin ≤ 3 × uln; creatinine ≤ 2 × uln or creatinine clearance rate ≥ 40ml/min; the left ventricular ejection fraction (lvef) measured by echocardiography or multigated acquisition (muga) scanning is within the normal range (\>50%); 6. the recipient and selected donor should be 0-3/10 hla-matched with same blood type; 7. patients who voluntarily participate in this clinical study and have signed an informed consent. exclusion criteria: 1. patients who have suffered from malignant tumors; 2. patients have suffered from hematopoietic failure after chemotherapy, and have undergone ineffective blood transfusion with unknown cause; 3. patients who have undergone class ii or above surgery within 4 weeks prior to enrollment; 4. suffering from life-threatening diseases other than mds; 5. allergic to the drugs in the research; 6. patient with severe cardiac insufficiency, including uncontrolled or symptomatic arrhythmia, congestive heart failure, myocardial infarction within 6 months, or any grade 3 (moderate) or grade 4 (severe) heart disease; 7. patients with test positive for hiv, hcv or hbv; 8. stroke or intracranial hemorrhage occurred within 6 months prior to enrollment; 9. warfarin or vitamin k antagonists (such as phenprocoumarin) is necessary for anticoagulation; 10. patients with mental illnesses or cognitive impairments; 11. patients have participated within the month prior to enrollment or patients are currently participating in other clinical trials; 12. there are other conditions that the investigators consider inappropriate for inclusion.
stress echocardiography study with regadenoson

Conditions: Heart Disease; Coronary Artery Disease

Summary: regadenoson is approved in the us under the brand name lexiscan for myocardial perfusion imaging. this study will test whether regadenoson is an appropriate stress agent for stress echocardiography.


Eligibility criteria:
inclusion criteria: * patients with a clinically indicated dobutamine echocardiogram showing normal wall motion at rest and abnormal wall motion with stress * patients with a clinically indicated dipyridamole echocardiogram showing normal perfusion and wall motion at rest and abnormal perfusion with or without abnormal wall motion with stress exclusion criteria: * any condition precluding the safe administration of dobutamine, dipyridamole or sonovue for echocardiography * pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control
in vitro models of liver and pancreatic cancer

Conditions: Cholangiocarcinoma; Hepatocellular Carcinoma; Pancreatic Neoplasm

Summary: the primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue. the secondary objective is to study the genetic and cellular biology of cancer of the liver, biliary tract and the pancreas. as well the investigators hope to compare molecular and cellular biology of cancer cells with normal cells as well as potentially test the efficacy of current and future anti-cancer therapies. samples will be collected from tissue that has been resected as part of the treatment for a patient diagnosed with liver, bile duct or pancreas cancer.


Eligibility criteria:
inclusion criteria: * all adult patients undergoing surgical resections for liver, biliary or pancreas cancers that are able to give informed consent. exclusion criteria: * patients aged \<18 or those who are unable to give informed consent.

Keywords: pancreas stem cells tumours in vitro models organoids cancer, bile duct liver
arestin - use in subjects with peri-implantitis

Conditions: Peri-Implantitis

Summary: the objective of the study is to evaluate the safety and effectiveness of arestin (minocycline hcl) 1 mg microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement. the hypothesis of the study is that arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. the primary efficacy measure will be the reduction of probing depth at day 180 as measured at qualifying implant sites.


Eligibility criteria:
inclusion criteria: * a minimum of one osseointegrated implant with a diagnosis of peri-implantitis * absence of any significant oral soft tissue pathology * at least one peri-implant site with an average of 2 probing depth readings between 5mm and 7mm (inclusive) when using a light force and with bleeding on probing within 30 seconds of the probing * confirmed evidence of pathologic bone loss * at least 1mm of keratinized gingiva present around the implant exclusion criteria: * pregnancy * allergy to tetracycline-class drug(s) * systemic medical condition(s) requiring antibiotic prophylaxis prior to invasive dental procedures * presence of active systemic infectious disease such as hepatitis, hiv, history of tuberculosis * diagnosis of clinically significant or unstable organic disease, or compromised healing potential * signs of untreated advanced periodontal disease and/or poor oral hygiene * subjects having a probing depth greater than 8mm at time of enrollment * subjects presenting with mobility of any dental implant * subjects having a qualifying implant under occlusal trauma or overloaded (as determined by the investigator)
role of the central nervous system in allergic rhinitis

Conditions: House Dust Mite Allergy

Summary: in order to evaluate the effects a nasal provocation on the activation of different brain regions, the investigators want to set up a clinical trial investigating the short-term effects of a nasal histamine provocation in healthy volunteers and allergic patients while in supine position under the functional mri device in order to visualize different brain regions.

evaluate the effects a nasal provocation on the activation of different brain regions

Eligibility criteria:
inclusion criteria: * patients with a positive skin prick test to grass pollen and with pollen allergic symptoms during the pollen season or patients with a negative skin prick test and with no allergic symptoms during the pollen season. * age \> 18 and \< 50 years * written informed consent * willingness to adhere to visit schedules * adequate contraceptive precautions in female patients with childbearing potential exclusion criteria: * current or recent (finished less than 2 years) immunotherapy against grass pollen. * systemic steroid treatment less than 6 weeks before the inclusion in the study. * nasal steroid spray, oral leukotriene antagonists or long-acting antihistamines less than 4 weeks before the inclusion. * presence of purulent secretions in nasal cavity. * severe septal deviation (septum reaching concha inferior or lateral nasal wall). * patient is pregnant or breastfeeding. * patient has any disorder of which the investigators feel at the time of evaluation for participation in the study that this may compromise the ability to give truly informed consent for participation in this study. * patient is currently enrolled in other investigational drug trial(s) or is receiving other investigational agent(s) for any other medical condition. * no independent medication management in daily life or disability to perform fine motoric handling of medication * patients with asthma will be excluded. * patients suffering from claustrophobia